104 related articles for article (PubMed ID: 29441922)
1. The impact of CYP3A5 on the metabolism of cyclosporine A and tacrolimus in the evaluation of efficiency and safety of immunosuppressive treatment in patients after kidney transplantation.
Sienkiewicz B; Hurkacz M; Kuriata-Kordek M; Augustyniak-Bartosik H; Wiela-HojeĊska A; Klinger M
Pharmazie; 2016 Oct; 71(10):562-565. PubMed ID: 29441922
[TBL] [Abstract][Full Text] [Related]
2. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
[TBL] [Abstract][Full Text] [Related]
5. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype.
Allegri L; Baldan F; Vallone C; Tulissi P; Gropuzzo M; Canelles MF; Righi E; Adani GL; Baccarani U; Montanaro D; Risaliti A; Damante G; Baraldo M
Transplant Proc; 2019 Nov; 51(9):2917-2920. PubMed ID: 31711577
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.
Flahault A; Anglicheau D; Loriot MA; Thervet E; Pallet N
Pharmacogenomics; 2017 Jan; 18(2):165-173. PubMed ID: 27977332
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients.
Hamzah S; Teh LK; Siew JS; Ahmad G; Wong HS; Zakaria ZA; Salleh MZ
Can J Physiol Pharmacol; 2014 Jan; 92(1):50-7. PubMed ID: 24383873
[TBL] [Abstract][Full Text] [Related]
14. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
van Gelder T; Hesselink DA
Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
[TBL] [Abstract][Full Text] [Related]
15. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
Clin Pharmacol Ther; 2011 Sep; 90(3):414-22. PubMed ID: 21753749
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
[TBL] [Abstract][Full Text] [Related]
17. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
18. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]